OS Therapies’s HER2 therapy prevents lung cancer recurrence in 33% patients

OS Therapies’s HER2 therapy prevents lung cancer recurrence in 33% patients

Submitted by admin on January 16, 2025 - 11:06am
Source: 
Clinical Trials Arena
News Tags: 
OS Therapies
lung cancer
HER2 Inhibitor
Headline: 
OS Therapies’s HER2 therapy prevents lung cancer recurrence in 33% patients
snippet: 

The OS Therapies study met its primary endpoint in enhancing event-free survival over 12 months when compared to historical control groups.

Do Not Allow Advertisers to Use My Personal information